Stacy Lindborg

Company: BrainStorm Cell Therapeutics

Job title: co-Chief Executive Officer

Seminars:

Promising Longer-Term Biomarker Data from NurOwn Program in ALS: Spotlight on NfL in EAP Extension Cohort 9:00 am

CSF samples were drawn during Phase 3 trial (3 treatments, debamestrocel and Placebo) and in participants who continued into EAP (6 treatments, debamestrocel) Trials enable hypothesis-generating data of the impact on a key marker of neuronal death related to longer-term treatment with an autologous cell therapy and the impact of delayed start to treatment Results…Read more

day: Conference Day One Morning

Reinventing the Surrogate Landscape: Innovating Regulatory Acceptable Endpoints Most Meaningful to People Living with ALS 2:05 pm

The recent accelerated approval brings new waves of promise for transformative ALS drugs to be approved based on surrogate markers that correlate with ALSFRS-R. With increasing demand to define more acceptable endpoints for ALS, collaborate with industry sponsors and regulatory experts to: Evaluate the potential of novel surrogate biomarkers that extend beyond ALSFRS-R to monitor…Read more

day: Pre-Conference Day